RANBAXY SIGNS LICENSING AGREEMENT FOR GENERIC PAIN PATCH

Indian drugmaker Ranbaxy Laboratories has announced that its wholly owned subsidiary, Ranbaxy Pharmaceuticals Canada, and Janssen-Ortho have entered into a licensing and supply agreement for a generic fentanyl patch, sold under Ranbaxy's label as RAN Fentanyl Transdermal System, in Canada. This is the second product to be commercialized by Ranbaxy as part of a licensing arrangement between the companies.

Ran Fentanyl Transdermal System is classified as an opioid analgesic drug indicated for the management of persistent, moderate to severe chronic pain. The patch will be available through pharmacies and wholesalers immediately.

Ranbaxy is the first India-based pharmaceutical company with a generic presence in Canada, the eighth largest pharmaceutical market in the world, according to the company. The company serves customers in more than 125 countries and has ground operations in 49 countries and manufacturing operations in eight countries.